BeLiver

At BeLiver, we increase the chances of beating liver cancer, and heterogenous cancers in general, by selecting the most suitable treatment for each patient. We are developing a personalized test platform that reveals a tumor’s unique biology, allowing us to predict the probability of treatment response. In less than one week, we can deliver a detailed report using proteomics and AI, outlining the likelihood of success for immunotherapies and chemotherapies. This cutting-edge approach not only gives every patient the chance to receive the most appropriate treatment at the first try, but it also has the potential to save hundreds of millions of euros in healthcare costs by significantly reducing ineffective treatments.